Therapeutic Antibody-Like Immunoconjugates against Tissue Factor with the Potential to Treat Angiogenesis-Dependent as Well as Macrophage-Associated Human Diseases

摘要: Accumulating evidence suggests that tissue factor (TF) is selectively expressed in pathological angiogenesis-dependent as well macrophage-associated human diseases. Pathological angiogenesis, the formation of neovasculature, involved many clinically significant diseases, notably cancer, age-related macular degeneration (AMD), endometriosis and rheumatoid arthritis (RA). Macrophage progression a variety such atherosclerosis viral infections (human immunodeficiency virus, HIV Ebola). It documented TF on angiogenic vascular endothelial cells (VECs) these diseases disease-associated macrophages. Under physiology condition, not by quiescent VECs monocytes but solely restricted some (such pericytes) are located outside blood circulation inner layer vessel walls. Here, we summarize expression VECs, macrophages other diseased cell types In for example, cancer also overexpress solid cancers leukemia. Moreover, our group recently reported cancer-initiating stem (CSCs) can serve novel oncotarget eradication CSCs without drug resistance. Furthermore, review discuss two generations TF-targeting therapeutic antibody-like immunoconjugates (ICON L-ICON1) antibody-drug conjugates currently being tested preclinical clinical studies treatment If efficacy safety proven current future trials, may provide approaches with potential to broadly impact regimen angiogenesis-dependent, macrophage-associated,